A review of central retinal artery occlusion: clinical presentation and management

Daniel Varma; Sudha Cugati; Andrew Lee; Celia Chen

doi:10.1038/eye.2013.25

A review of central retinal artery occlusion: clinical presentation and management

Daniel Varma, Sudha Cugati, Andrew Lee, Celia Chen

Research output: Contribution to journal › Review article › peer-review

283 Citations (Scopus)

Abstract

Central retinal artery occlusion (CRAO) is an ophthalmic emergency and the ocular analogue of cerebral stroke. Best evidence reflects that over three-quarters of patients suffer profound acute visual loss with a visual acuity of 20/400 or worse. This results in a reduced functional capacity and quality of life. There is also an increased risk of subsequent cerebral stroke and ischaemic heart disease. There are no current guideline-endorsed therapies, although the use of tissue plasminogen activator (tPA) has been investigated in two randomized controlled trials. This review will describe the pathophysiology, epidemiology, and clinical features of CRAO, and discuss current and future treatments, including the use of tPA in further clinical trials.

Original language	English
Pages (from-to)	688-697
Number of pages	10
Journal	Eye
Volume	27
Issue number	6
DOIs	https://doi.org/10.1038/eye.2013.25
Publication status	Published - Jun 2013

Keywords

central retinal artery occlusion
management
thrombolysis

Access to Document

10.1038/eye.2013.25

Cite this

@article{87f917776aa84c81b5b0dcc3ea026298,

title = "A review of central retinal artery occlusion: clinical presentation and management",

abstract = "Central retinal artery occlusion (CRAO) is an ophthalmic emergency and the ocular analogue of cerebral stroke. Best evidence reflects that over three-quarters of patients suffer profound acute visual loss with a visual acuity of 20/400 or worse. This results in a reduced functional capacity and quality of life. There is also an increased risk of subsequent cerebral stroke and ischaemic heart disease. There are no current guideline-endorsed therapies, although the use of tissue plasminogen activator (tPA) has been investigated in two randomized controlled trials. This review will describe the pathophysiology, epidemiology, and clinical features of CRAO, and discuss current and future treatments, including the use of tPA in further clinical trials.",

keywords = "central retinal artery occlusion, management, thrombolysis",

author = "Daniel Varma and Sudha Cugati and Andrew Lee and Celia Chen",

year = "2013",

month = jun,

doi = "10.1038/eye.2013.25",

language = "English",

volume = "27",

pages = "688--697",

journal = "Eye",

issn = "0950-222X",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - A review of central retinal artery occlusion: clinical presentation and management

AU - Varma, Daniel

AU - Cugati, Sudha

AU - Lee, Andrew

AU - Chen, Celia

PY - 2013/6

Y1 - 2013/6

N2 - Central retinal artery occlusion (CRAO) is an ophthalmic emergency and the ocular analogue of cerebral stroke. Best evidence reflects that over three-quarters of patients suffer profound acute visual loss with a visual acuity of 20/400 or worse. This results in a reduced functional capacity and quality of life. There is also an increased risk of subsequent cerebral stroke and ischaemic heart disease. There are no current guideline-endorsed therapies, although the use of tissue plasminogen activator (tPA) has been investigated in two randomized controlled trials. This review will describe the pathophysiology, epidemiology, and clinical features of CRAO, and discuss current and future treatments, including the use of tPA in further clinical trials.

AB - Central retinal artery occlusion (CRAO) is an ophthalmic emergency and the ocular analogue of cerebral stroke. Best evidence reflects that over three-quarters of patients suffer profound acute visual loss with a visual acuity of 20/400 or worse. This results in a reduced functional capacity and quality of life. There is also an increased risk of subsequent cerebral stroke and ischaemic heart disease. There are no current guideline-endorsed therapies, although the use of tissue plasminogen activator (tPA) has been investigated in two randomized controlled trials. This review will describe the pathophysiology, epidemiology, and clinical features of CRAO, and discuss current and future treatments, including the use of tPA in further clinical trials.

KW - central retinal artery occlusion

KW - management

KW - thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=84879407320&partnerID=8YFLogxK

U2 - 10.1038/eye.2013.25

DO - 10.1038/eye.2013.25

M3 - Review article

SN - 0950-222X

VL - 27

SP - 688

EP - 697

JO - Eye

JF - Eye

IS - 6

ER -

A review of central retinal artery occlusion: clinical presentation and management

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this